[go: up one dir, main page]

WO2025085109A3 - Methods of preventing post-traumatic osteoarthritis using metformin - Google Patents

Methods of preventing post-traumatic osteoarthritis using metformin Download PDF

Info

Publication number
WO2025085109A3
WO2025085109A3 PCT/US2024/028754 US2024028754W WO2025085109A3 WO 2025085109 A3 WO2025085109 A3 WO 2025085109A3 US 2024028754 W US2024028754 W US 2024028754W WO 2025085109 A3 WO2025085109 A3 WO 2025085109A3
Authority
WO
WIPO (PCT)
Prior art keywords
metformin
methods
osteoarthritis
traumatic osteoarthritis
post
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/028754
Other languages
French (fr)
Other versions
WO2025085109A2 (en
Inventor
Diane Renee WAGNER
Todd Owen MCKINLEY
Roman Michael NATOLI
Uma SANKAR-DAVIS
Sonali J. KARNIK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University
Indiana University Bloomington
Original Assignee
Indiana University
Indiana University Bloomington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University, Indiana University Bloomington filed Critical Indiana University
Publication of WO2025085109A2 publication Critical patent/WO2025085109A2/en
Publication of WO2025085109A3 publication Critical patent/WO2025085109A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed herein are methods of using metformin or a pharmaceutically acceptable salt thereof, such as intraarticular administration of metformin, to treat injured joints. Also disclosed are methods of using metformin to prevent the progression of osteoarthritis, such as osteoarthritis resulting from an injury, or post-traumatic osteoarthritis. Further disclosed are dosing regimens and compositions of metformin for the treatment and prevention of post-traumatic osteoarthritis.
PCT/US2024/028754 2023-05-11 2024-05-10 Methods of preventing post-traumatic osteoarthritis using metformin Pending WO2025085109A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363465651P 2023-05-11 2023-05-11
US63/465,651 2023-05-11

Publications (2)

Publication Number Publication Date
WO2025085109A2 WO2025085109A2 (en) 2025-04-24
WO2025085109A3 true WO2025085109A3 (en) 2025-06-05

Family

ID=95448957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/028754 Pending WO2025085109A2 (en) 2023-05-11 2024-05-10 Methods of preventing post-traumatic osteoarthritis using metformin

Country Status (1)

Country Link
WO (1) WO2025085109A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130324463A1 (en) * 2012-05-24 2013-12-05 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor for modifying food intake and regulating food preference
US20140186306A1 (en) * 2012-09-28 2014-07-03 Paul Ronald Plante Novel ampk agonist compositions and methods of use
US20210085827A1 (en) * 2015-08-19 2021-03-25 University Of Iowa Research Foundation Preventative therapy for post-traumatic osteoarthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130324463A1 (en) * 2012-05-24 2013-12-05 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor for modifying food intake and regulating food preference
US20140186306A1 (en) * 2012-09-28 2014-07-03 Paul Ronald Plante Novel ampk agonist compositions and methods of use
US20210085827A1 (en) * 2015-08-19 2021-03-25 University Of Iowa Research Foundation Preventative therapy for post-traumatic osteoarthritis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIM ET AL.: "Metformin as a potential disease-modifying drug in osteoarthritis: a systematic review of pre-clinical and human studies", OSTEOARTHRITIS AND CARTILAGE, vol. 30, 2022, pages 1434 - 1442, XP087009859, DOI: 10.1016/j.joca.2022.02.596 *
MODI JUHI: "Metformin vs Metformin Hydrochloride: Similarities & Differences", BUZZRX, 11 December 2023 (2023-12-11), XP093333954, Retrieved from the Internet <URL:https://www.buzzrx.com/blog/metformin-vs-metformin-hydrochloride-similarities-differences> *
WANG YIFEI, SONG WEI, LI YIMING, ZHOU ZHEKUN, LI CHENKAI, YU WEILIN, HE YAOHUA: "Metformin-loaded PLGA microspheres combined with an in situ-formed injectable SA/BG hydrogel alleviate rotator cuff muscle degeneration", MATERIALS TODAY BIO, ELSEVIER, vol. 23, 1 December 2023 (2023-12-01), pages 100874, XP093333957, ISSN: 2590-0064, DOI: 10.1016/j.mtbio.2023.100874 *

Also Published As

Publication number Publication date
WO2025085109A2 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
MX2021004431A (en) Novel processes.
MA40887A (en) NEW DERIVATIVES OF 4-METHOXY PYRROLE OR THEIR SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
MX2025008327A (en) Compositions and methods for treating cns disorders
RU95107403A (en) Benzoxazinone compounds, pharmaceutical compositions, methods of inhibition of reverse transcriptase, prophylaxis and treatment, synergistic combinations and method of synthesis of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihyd- -ro-2h-3,1-benzoxazine-2-one
BG103521A (en) Substituted pyrimidinon and pyridon compounds and methods for their application
WO2022115381A8 (en) Compositions and methods for treating cns disorders
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
EP4606428A3 (en) Heparin-associated polypeptides and uses thereof
CA3242612A1 (en) Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions
WO2024189598A3 (en) Acylsulfonamide kat6a inhibitors
MX2022009197A (en) Methods of treatment for alpha-1 antitrypsin deficiency.
EP4574822A3 (en) Compounds and compositions for use in treating skin disorders
NZ753781A (en) Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
WO2025085109A3 (en) Methods of preventing post-traumatic osteoarthritis using metformin
WO2022106902A8 (en) Benzenesulfonamide derivatives and uses thereof
AU2024210943A1 (en) Prmt5 inhibiting compounds and uses thereof
EA202092472A1 (en) HIGH-MOLECULAR HYALURONIC ACID FOR TREATMENT AND PREVENTION OF SEVERE DISEASE OF THE EYE SURFACE
MX2021009082A (en) Chemical compounds.
MX2021003508A (en) 5-azaindazole derivatives as adenosine receptor antagonists.
WO2023230348A3 (en) Dosage regimens for treatment of dengue infection
WO2020096916A3 (en) Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
MX2025001111A (en) Novel sulfonamides and their use as neuroprotective and/or neurorestorative agents
DE602004006024D1 (en) PHARMACEUTICAL COMPOSITION WITH A ZINC / HYALURONATE COMPLEX FOR THE TREATMENT OF MULTIPLE SCLEROSIS
PH12021550093A1 (en) Compounds for use in the treatment of fascioliasis
AU2024208998A1 (en) Lanifibranor formulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24880318

Country of ref document: EP

Kind code of ref document: A2